Tempest Therapeutics price target lowered to $5 from $8 at Piper Sandler
The Fly

Tempest Therapeutics price target lowered to $5 from $8 at Piper Sandler

Piper Sandler lowered the firm’s price target on Tempest Therapeutics (TPST) to $5 from $8 and keeps an Overweight rating on the shares following quarterly results. The FDA issued a “study may proceed” letter for the planned Phase III trial of 600mg BID amezalpat + Tecentriq+Avastin vs. Tecentriq+Avastin in 1st-line hepatocellular carcinoma. Tempest anticipates starting the study in Q1 2025 and reporting data within 3 years.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App